Burchert Andreas
Universitätsklinikum Gießen und Marburg, Campus Marburg, Klinik für Hämatologie, Onkologie und Immunologie, Carreras Leukemia Center, Philipps-Universität Marburg, Baldingerstr., 35043, Marburg, Deutschland.
Inn Med (Heidelb). 2022 Oct;63(10):1051-1058. doi: 10.1007/s00108-022-01388-8. Epub 2022 Aug 15.
Clonal hematopoiesis of indeterminate potential (CHIP) refers to hematopoiesis from stem cells with mutations in leukemia-associated driver genes. These confer increased stress tolerance and expansive potential to stem cell clones. Patients with CHIP are hematologically healthy. The main risk factor for the development of CHIP is age or chronic inflammatory processes associated with aging, so-called "inflammaging". Therefore, the correlation of age-associated comorbidities with the detection of CHIP is not coincidental. CHIP is associated with, among other things, a significantly increased risk of cardiovascular disease and increased all-cause mortality. From a pathomechanistic perspective, CHIP leads to increased secretion of proinflammatory cytokines. It is also associated with a significantly increased risk of developing hematologic neoplasms. Thus, the treatment of CHIP could suppress the occurrence of hematologic neoplasms and prevent age-associated diseases.
不确定潜能的克隆性造血（CHIP）是指源自白血病相关驱动基因突变干细胞的造血过程。这些突变赋予干细胞克隆更高的应激耐受性和增殖潜能。CHIP患者血液学上是健康的。CHIP发生的主要危险因素是年龄或与衰老相关的慢性炎症过程，即所谓的“炎症衰老”。因此，年龄相关合并症与CHIP检测之间的相关性并非偶然。CHIP与多种情况相关，尤其是心血管疾病风险显著增加和全因死亡率升高。从病理机制角度来看，CHIP导致促炎细胞因子分泌增加。它还与发生血液系统肿瘤的风险显著增加相关。因此，CHIP的治疗可能会抑制血液系统肿瘤的发生并预防与年龄相关的疾病。
